Home > Articles > NMN vs NR: how the two NAD+ precursors compare in human research
NMN vs NR: how the two NAD+ precursors compare in human research
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the two NAD+ precursors that research and marketing compare most often. They are close chemical relatives: NMN is essentially NR with a phosphate group attached. That one-step difference affects how each is thought to reach cells. It has not been shown to produce different outcomes in people.
This explainer compares the two molecules as precursor against precursor. For how a precursor differs from the coenzyme itself, see NMN vs NAD+: precursor and coenzyme, explained. For the full pathway map, see the NAD+ guide.
The short answer
NR and NMN both feed the NAD+ salvage pathway, and they sit one enzymatic step apart [1].
Each has been studied in human trials that are mostly small and short, and most of them randomized. They report changes in blood NAD+ or related metabolites alongside safety laboratory tests [5][6][10][11].
The sources reviewed here include no randomized trial that tested NMN and NR directly against each other. Published comparisons are built from separate studies [1][3].
A 2026 PRISMA-guided systematic review collected preclinical and clinical evidence on NAD+ supplementation. It is a useful map of how much of this literature comes from animals and how much from people [2].
Biochemistry: one phosphate apart
The NR route
Inside cells, enzymes called nicotinamide riboside kinases (NRK1 and NRK2) add a phosphate to NR, which turns it into NMN. NMN adenylyltransferases (NMNATs) then convert NMN to NAD+ [1].
NR can also be broken down to nicotinamide, which re-enters NAD+ synthesis through the NAMPT step of the salvage pathway. A share of any NR intake may therefore reach NAD+ by an indirect route.
The NMN route
NMN is already the molecule that NRK produces. On paper, that puts it one step closer to NAD+. The practical question is whether intact NMN crosses cell membranes.
Mouse research proposed a dedicated NMN transporter, Slc12a8, and other research groups have disputed that finding. An alternative model holds that much extracellular NMN is first dephosphorylated to NR. In that model, NR is taken up and then converted back to NMN by NRK inside the cell. If the model holds, the two precursors share the same entry step in many tissues.
The question is not settled. Human trials cannot resolve it, because they measure metabolites in blood rather than tracing where each molecule goes inside tissues.
Related molecules under study
Dihydronicotinamide riboside (NRH) is a reduced form of NR. A 2019 study reported that it raised NAD+ concentrations strongly in cultured cells and in mice [4]. That work is preclinical. A 2026 review compares NMN and NR with a different compound, PQQ, and discusses combining them. It, too, draws on separate studies rather than direct comparisons [3].
Feature | NR | NMN |
|---|---|---|
Chemical relationship | Nucleoside (no phosphate) | Nucleotide (NR plus phosphate) |
Step into NAD+ synthesis | Phosphorylated by NRK1/2 to NMN | Converted by NMNATs to NAD+ |
Cell entry | Nucleoside transport, then NRK | Debated: proposed transporter vs conversion to NR first |
Human trial base | Several human trials [5][6][7][8][9] | Several human trials [10][11][12][13][14][15][16][17] |
Head-to-head randomized trial | None in sources reviewed | None in sources reviewed |
What human NR trials have measured
Healthy middle-aged and older adults. Martens and colleagues ran a randomized, placebo-controlled crossover study. They reported that NR was well tolerated and elevated NAD+ levels [5].
Healthy overweight adults. Conze and colleagues ran a randomized, double-blind, placebo-controlled trial in 140 people over eight weeks, comparing three intake levels with placebo. The trial assessed safety measures and NAD+ metabolism, including whole-blood NAD+ [6].
Adults with obesity. A small trial by Remie and colleagues reported changes in body composition and in skeletal muscle acetylcarnitine [7].
Neuronal-origin vesicles. Vreones and colleagues reported that oral NR raised NAD+. They also reported lower levels of neurodegeneration-related biomarkers in plasma extracellular vesicles enriched for neuronal origin. These are biomarker readouts, not clinical outcomes [8].
COPD. A randomized, placebo-controlled trial in adults with COPD measured markers of airway inflammation during NR supplementation [9].
The nicotinamide riboside research page covers these trials in more detail.
What human NMN trials have measured
Healthy adults. A 12-week randomized, placebo-controlled trial in healthy participants reported higher blood NAD+ and no abnormalities in physiological or laboratory tests [10].
Healthy middle-aged adults. A 60-day multicenter trial in 80 participants compared three intake levels with placebo. It reported rises in blood NAD in all NMN groups and no safety concerns on clinical and laboratory measures [11].
A pharmaceutical-grade formulation. Pencina and colleagues studied MIB-626, a microcrystalline formulation of NMN. They reported increases in circulating NAD+ and its metabolome in middle-aged and older adults [12]. A later physiologic study from the same group examined NAD+ augmentation in overweight or obese middle-aged and older adults [13].
Physiological endpoints. A few NMN trials looked beyond blood metabolites:
Muscle insulin sensitivity in women with prediabetes [14]
Aerobic capacity measures in amateur runners [15]
Arterial stiffness alongside NAD+ metabolism over a longer period [16]
Metabolism, sleep and NAD+ biosynthesis in healthy middle-aged Japanese men [17]
Each of these is a single, small study.
Why cross-trial comparisons mislead
It is tempting to line up the NR rows against the NMN rows and pick a winner. The trials differ on almost every variable that matters:
Population: age, sex, body weight and health status
Duration: weeks in some trials, months in others
Formulation: for example, salt forms or crystal polymorphs
Sample type: whole blood, isolated blood cells, plasma or muscle
Assay: the laboratory method used to measure NAD+
A larger NAD+ rise in one trial than in another can reflect any of these differences. It does not show that one precursor is stronger. The reviews that compare precursors draw on separate studies, so they cannot substitute for a direct comparison [1][3].
The measurement problem
What counts as "raising NAD+" depends on where and how NAD+ is measured.
A 2026 study in Nature Metabolism by Trętowicz and colleagues reported that human whole-blood NAD+ did not vary with age or with lifestyle interventions, while NR supplementation did raise it [18]. Whole blood can therefore register a precursor effect while staying flat across age groups.
An earlier study of human tissue samples reported age-associated changes in oxidative stress and NAD+ metabolism [19]. Tissue and blood may simply behave differently, which is one reason a single blood number says little about any particular tissue.
For units, sample types and reference ranges, see Reading an NAD+ test report.
U.S. regulatory status in brief
Both precursors are sold in the U.S. as dietary supplement ingredients. Under the dietary supplement framework, products do not need FDA approval before sale, and FDA can act on unsafe or misbranded products after they reach the market [20].
NMN's position changed in recent years. A law-firm summary reports that FDA concluded in September 2025 that NMN is lawful in dietary supplements, a departure from its earlier position [21]. The related citizen petition is public in docket FDA-2023-P-0872 [22]. Neither status is an FDA finding that either precursor works.
The full timeline is on Is NAD+ legal? NMN, NR and IV NAD+ under U.S. rules.
Tools for comparing NAD+ measurements
Readers following this research often want to see what an NAD+ measurement looks like in practice. Laboratory blood tests are the product category most relevant to this topic, and their documentation varies widely. A well-documented test makes its numbers interpretable; a vague one produces a figure with no context. These criteria separate the two:
Sample type stated: whole blood, dried blood spot or plasma. Results from different sample types cannot be compared directly.
Method published: for example, LC-MS/MS or an enzymatic cycling assay, with validation data available.
What is reported: NAD+ alone, or NAD+ with NADH and related metabolites. Units should be explicit.
Reference data: how the reference range was derived, and from what population.
Price transparency: the total cost, including shipping and any retest fees.
Data privacy: who stores the results, for how long, and whether they are shared.
Our NAD+ test buyer's guide compares how at-home blood tests work. For background reading, see the evidence-graded NAD+ books list.
Affiliate arrangements and research standards are described on the page explaining how this site works.
Frequently asked questions
Is NMN or NR better at raising NAD+?
None of the sources reviewed here include a randomized head-to-head trial that answers this. Each precursor has raised blood NAD+ or related metabolites in separate trials. Differences in population, formulation, duration and assay make cross-trial comparisons unreliable [1][3].
Does NMN enter cells directly?
This is unsettled. A proposed transporter, Slc12a8, has been disputed. An alternative model has NMN converted to NR outside the cell before uptake, which would put both precursors on the same entry route.
Do these trials show health outcomes?
Most trials measured the blood NAD+ metabolome and safety labs in small groups over weeks to months. A few measured physiological endpoints such as muscle insulin sensitivity, aerobic capacity or arterial stiffness. These were single, small studies and have not established clinical outcomes [14][15][16].
What does a whole-blood NAD+ test capture?
It reports the NAD+ concentration in one blood sample, measured by one specific method. A 2026 study found whole-blood NAD+ did not vary with age, although NR supplementation raised it [18]. Without knowing the method and the reference data, a single number is hard to interpret.
Related on this site
NAD+ explained: biochemistry, precursors, testing and human evidence
Nicotinamide riboside research: what human trials have measured
Reading an NAD+ test report: units, sample types and reference ranges
Last updated: 20 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.